BR0308403A - Method for treating an eye disorder of a human or veterinary patient, and using a compound - Google Patents
Method for treating an eye disorder of a human or veterinary patient, and using a compoundInfo
- Publication number
- BR0308403A BR0308403A BR0308403-5A BR0308403A BR0308403A BR 0308403 A BR0308403 A BR 0308403A BR 0308403 A BR0308403 A BR 0308403A BR 0308403 A BR0308403 A BR 0308403A
- Authority
- BR
- Brazil
- Prior art keywords
- corneal
- eye
- urea
- compound
- guanidinium
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 208000030533 eye disease Diseases 0.000 title abstract 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 abstract 3
- 238000011282 treatment Methods 0.000 abstract 3
- 102000016611 Proteoglycans Human genes 0.000 abstract 2
- 108010067787 Proteoglycans Proteins 0.000 abstract 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 abstract 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 abstract 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 239000004202 carbamide Substances 0.000 abstract 2
- -1 citadine Chemical compound 0.000 abstract 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 abstract 2
- 238000004090 dissolution Methods 0.000 abstract 2
- 230000002255 enzymatic effect Effects 0.000 abstract 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 abstract 2
- 150000003672 ureas Chemical class 0.000 abstract 2
- FMBVHKPWDJQLNO-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-5-nitroindazole Chemical compound N1=CC2=CC([N+](=O)[O-])=CC=C2N1CC1=CC=CC(F)=C1 FMBVHKPWDJQLNO-UHFFFAOYSA-N 0.000 abstract 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 abstract 1
- 229930024421 Adenine Natural products 0.000 abstract 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 abstract 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 206010055665 Corneal neovascularisation Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 abstract 1
- 206010065630 Iris neovascularisation Diseases 0.000 abstract 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 201000002154 Pterygium Diseases 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 1
- 229960000643 adenine Drugs 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 abstract 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 abstract 1
- 235000011130 ammonium sulphate Nutrition 0.000 abstract 1
- 230000000340 anti-metabolite Effects 0.000 abstract 1
- 229940100197 antimetabolite Drugs 0.000 abstract 1
- 239000002256 antimetabolite Substances 0.000 abstract 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 abstract 1
- 201000000159 corneal neovascularization Diseases 0.000 abstract 1
- 210000003683 corneal stroma Anatomy 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 229940104302 cytosine Drugs 0.000 abstract 1
- IZFHEQBZOYJLPK-UHFFFAOYSA-N dihydrolipoic acid Chemical compound OC(=O)CCCCC(S)CCS IZFHEQBZOYJLPK-UHFFFAOYSA-N 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 abstract 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 125000003835 nucleoside group Chemical group 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 229920001451 polypropylene glycol Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000036573 scar formation Effects 0.000 abstract 1
- 229940104230 thymidine Drugs 0.000 abstract 1
- 229940035893 uracil Drugs 0.000 abstract 1
- 229940116269 uric acid Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
"MéTODO PARA TRATAMENTO DE UM DISTúRBIO DO OLHO DE UM PACIENTE HUMANO OU VETERINáRIO, E, USO DE UM COMPOSTO". Métodos e preparações para tratamento de distúrbios do olho e/ou dissolução de proteoglicanos da córnea, cicatrização organizada do estroma corneal, amolecimento da córnea para correção refrativa não cirúrgica da vista, remoção de névoa e opacificação corneal, inibição de fibroblastos e prevenção de fibrose corneal e formação de cicatrizes, tratamento de pterígios, tratamentos de neovascularização corneal e neovascularização da íris. São admistradas ao olho, em montantes terapeuticamente eficazes, preparações contendo a) uréia, b) derivados de uréia (por exemplo, hidroxiuréia, tiouréia), c) antimetabólitos, e) uréia, derivados de uréia, proteínas não enzimáticas, nucleosídeos, nucleotídeos e seus derivados (por exemplo, adenina, adenosina, citosina, citadina, guanina, guanitadina, guanidínio, cloreto de guanidínio, sais de guanidínio, timidina, timitadina, uradina, uracila, cisteína), ácido tióctico reduzido, ácido úrico, acetil salicilato de cálcio, sulfato de amónio, álcool isopropílico, etanol, polietileno glicol, polipropileno glicol ou outro composto capaz de causar dissolução não enzimática dos proteoglicanos da córnea ou f) quaisquer das combinações possíveis dos mesmos."METHOD FOR TREATMENT OF A DISTURBANCE OF THE EYE OF A HUMAN OR VETERINARY PATIENT, AND USE OF A COMPOUND." Methods and preparations for treating eye disorders and / or corneal proteoglycan dissolution, organized corneal stroma healing, corneal softening for non-surgical refractive eye correction, corneal fogging and opacification, fibroblast inhibition and corneal fibrosis prevention and scar formation, pterygium treatment, corneal neovascularization and iris neovascularization treatments. Therapeutically effective amounts are administered to the eye, preparations containing a) urea, b) urea derivatives (eg hydroxyurea, thiourea), c) antimetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and its derivatives (e.g. adenine, adenosine, cytosine, citadine, guanine, guanitadine, guanidinium, guanidinium chloride, guanidinium salts, thymidine, thymidadine, uradine, uracil, cysteine), reduced thioctic acid, uric acid, calcium acetyl salicylate , ammonium sulfate, isopropyl alcohol, ethanol, polyethylene glycol, polypropylene glycol or other compound capable of causing non-enzymatic dissolution of the corneal proteoglycans or f) any of the possible combinations thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36397902P | 2002-03-14 | 2002-03-14 | |
| PCT/US2003/007700 WO2003077898A1 (en) | 2002-03-14 | 2003-03-14 | Agents for corneal or intrastromal administration to treat or prevent disorders of the eye |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0308403A true BR0308403A (en) | 2005-01-18 |
Family
ID=28041849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0308403-5A BR0308403A (en) | 2002-03-14 | 2003-03-14 | Method for treating an eye disorder of a human or veterinary patient, and using a compound |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1482922A4 (en) |
| JP (1) | JP2005522464A (en) |
| KR (1) | KR20040094793A (en) |
| CN (1) | CN1642536A (en) |
| AU (2) | AU2003213858A1 (en) |
| BR (1) | BR0308403A (en) |
| CA (1) | CA2478965A1 (en) |
| MX (1) | MXPA04008776A (en) |
| RU (1) | RU2363459C2 (en) |
| WO (1) | WO2003077898A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030199574A1 (en) | 2000-03-02 | 2003-10-23 | Vitreo-Retinal Technologies, Inc. | Treatment of ophthalmic disorders using urea and urea derivatives |
| CN101231121B (en) * | 2007-01-24 | 2012-06-13 | 泰州乐金电子冷机有限公司 | Pallet stretching-out device for refrigerator |
| CN102859344A (en) * | 2010-03-12 | 2013-01-02 | 独立行政法人理化学研究所 | Clarification reagents for biological materials and uses thereof |
| RU2442609C1 (en) * | 2010-11-12 | 2012-02-20 | Озеров Александр Александрович | The solution product for soft and hard contact lenses |
| EP2711682B1 (en) | 2011-05-20 | 2019-07-10 | Riken | Clarifying reagent for biological materials and use thereof |
| WO2015022883A1 (en) | 2013-08-14 | 2015-02-19 | 独立行政法人理化学研究所 | Composition for preparing biomaterial with excellent light-transmitting property, and use thereof |
| DE102013110608A1 (en) * | 2013-09-26 | 2015-03-26 | Florian Lang | Substance for inhibiting tissue calcification, tissue fibrosis and age-associated diseases |
| CN110237238A (en) * | 2019-08-02 | 2019-09-17 | 山东省眼科研究所 | MANF is promoting the application in corneal injury reparation |
| US12350250B2 (en) | 2022-04-01 | 2025-07-08 | The Regent Of The University Of Colorado, A Body Corporate | Aggrelytes for treating ocular conditions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2094031C1 (en) * | 1992-04-09 | 1997-10-27 | Малое государственное предприятие "Научно-экспериментальное производство" | Method of prophylaxis of morbid-grown vessels of cornea after perforating and layer keratoplasty |
| US5470881A (en) * | 1993-09-09 | 1995-11-28 | West Virginia University Research Corporation | Urea ophthalmic ointment and solution |
| RU2082434C1 (en) * | 1994-12-19 | 1997-06-27 | Уфимский научно-исследовательский институт глазных болезней | Ocular ointment |
| ATE396734T1 (en) * | 1999-03-02 | 2008-06-15 | Vitreo Retinal Technologies In | AGENTS FOR INTRAVITREAL ADMINISTRATION FOR THE TREATMENT OR PREVENTION OF EYE DISEASES |
| ATE428412T1 (en) * | 2002-02-13 | 2009-05-15 | Vitreo Retinal Technologies In | TREATMENT OF EYE DISEASES WITH UREA AND UREA DERIVATIVES |
-
2003
- 2003-03-14 WO PCT/US2003/007700 patent/WO2003077898A1/en not_active Ceased
- 2003-03-14 JP JP2003575951A patent/JP2005522464A/en active Pending
- 2003-03-14 AU AU2003213858A patent/AU2003213858A1/en not_active Abandoned
- 2003-03-14 KR KR10-2004-7014329A patent/KR20040094793A/en not_active Ceased
- 2003-03-14 CA CA002478965A patent/CA2478965A1/en not_active Abandoned
- 2003-03-14 BR BR0308403-5A patent/BR0308403A/en not_active Application Discontinuation
- 2003-03-14 RU RU2004129761/14A patent/RU2363459C2/en not_active Application Discontinuation
- 2003-03-14 MX MXPA04008776A patent/MXPA04008776A/en not_active Application Discontinuation
- 2003-03-14 CN CNA038059681A patent/CN1642536A/en active Pending
- 2003-03-14 EP EP03711552A patent/EP1482922A4/en not_active Withdrawn
-
2009
- 2009-05-13 AU AU2009201897A patent/AU2009201897B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009201897A1 (en) | 2009-06-04 |
| AU2009201897B2 (en) | 2011-09-15 |
| EP1482922A1 (en) | 2004-12-08 |
| WO2003077898A1 (en) | 2003-09-25 |
| RU2363459C2 (en) | 2009-08-10 |
| EP1482922A4 (en) | 2005-06-08 |
| RU2004129761A (en) | 2005-06-10 |
| CN1642536A (en) | 2005-07-20 |
| AU2003213858A1 (en) | 2003-09-29 |
| JP2005522464A (en) | 2005-07-28 |
| CA2478965A1 (en) | 2003-09-25 |
| MXPA04008776A (en) | 2005-04-19 |
| KR20040094793A (en) | 2004-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG105867A (en) | MEANS FOR APPLICATION IN THE GLASS BODY IN TREATMENT OR DISEASE OF OCCUPATIONAL DISORDERS | |
| AU1172997A (en) | 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmaceutically acceptable acid addition salt thereof for use in the preparation of a non-oral medicament, and for treatment of diseases and disorders | |
| BR0308403A (en) | Method for treating an eye disorder of a human or veterinary patient, and using a compound | |
| BR9909474A (en) | Forms ii, crystalline ev of 5,6-dichloro-2- (isopropylamino) -1-beta-1-ribofuranosyl -1h-benzimidazole, 5,6-dichloro-2- (isopropylamino) -1-beta- ethanol solvate l-ribofuranosyl -1h-benzimidazole, composition, compound, use of 5,6-dichloro-2- (isopropylamino) -1-beta-l-ribofuranosyl -1h-benzimidazole, and processes for the treatment of a viral infection in a and for the production of 5,6-dichloro-2- (isopropylamino) -1-beta-1-ribofuranosyl -1h-benzimidazole | |
| BR0316397A (en) | Substituted aryl thioureas and related compounds as viral replication inhibitors | |
| AP1853A (en) | Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents. | |
| BR9914097A (en) | Compound, use of it, pharmaceutical composition and method of prophylaxis or treatment of a viral infection and process for preparing the compound | |
| KR950701350A (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES WITH INTERFERON WHILE REDUCING SIDE EFFECTS | |
| TR200200234T2 (en) | Tyrosine Protein kinase SYK purine derivatives inhibitors | |
| Cronstein | The antirheumatic agents sulphasalazine and methotrexate share an anti-inflammatory mechanism | |
| BR0313464A (en) | Heterobiaryl derivatives as matrix metalloproteinase inhibitors | |
| CY1110770T1 (en) | USE OF (R) - (ALOGENOBENZYLOXY) benzylamine-propanamides as selective sodium and / or calcium channel modulators | |
| DK0658110T3 (en) | Use of norastemizole for the treatment of allergic rhinitis | |
| BRPI0410050A (en) | method of treatment or prophylaxis of psychotic disorders, disorders of intellectual impairment or diseases or conditions in which alpha-nicotinic receptor modulation is beneficial, pharmaceutical composition, method of treatment or prophylaxis of diseases, use of a compound, compound, and , method of preparing a compound | |
| NO994165L (en) | Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, travel sickness and dizziness | |
| CA2314571A1 (en) | Methods and compositions for treating diseases and conditions of the eye | |
| NO20023486L (en) | Pyrrole-type compounds, compounds containing compounds and their use in the treatment of cancer and viral diseases | |
| BR0317289A (en) | Method for treating movement disorders using barbituric acid derivatives | |
| EP0286825A3 (en) | Use of 3'-fluro-3' deoxythymidine for the manufacture of a medicament for the treatment of virus infections | |
| DE60011637D1 (en) | DIOXOLAN NUCLEOSIDE ANALOGS FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | |
| DK0500953T3 (en) | Potentiator of antineoplastic action and antineoplastic agent | |
| BRPI0410878A (en) | benzothiazole derivatives and their uses in the treatment of adenosine a2a receptor-related diseases | |
| Shinkai et al. | Valacyclovir | |
| BR0015024A (en) | Application of 2-imidazolyl substituted carbinols for the preparation of a medicine for the treatment or prophylaxis of diseases caused by ischemic conditions | |
| EP3572079B1 (en) | Etamsylate for treatment of herpes virus infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: PARA INT.CL: A61K 31/17, A61P 27/02, A61P 41/00 Ipc: A61K 31/17 (2011.01), A61P 27/02 (2011.01), A61P 4 |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |